Gentian Diagnostics ASA (DE:6FK) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Gentian Diagnostics ASA has announced the successful completion of the optimization phase for its NT-proBNP assay, with further development phases pending. The company projects a research-use-only launch in the latter half of 2025, with a full commercial release contingent on external regulatory clearance timelines. Their breakthrough assay, designed for high-throughput analyzers, promises increased lab productivity and cost reduction, distinguishing itself by measuring total NT-proBNP levels.
For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.
